TD Cowen Remains a Buy on Vertex Pharmaceuticals (VRTX)
TD Cowen analyst Phil Nadeau maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of ...
Scotiabank Sticks to Their Buy Rating for EyePoint Pharmaceuticals (EYPT)
In a report released today, Greg Harrison from Scotiabank maintained a Buy rating on EyePoint Pharmaceuticals (EYPT – Research Report), with a ...
Vertex Pharmaceuticals Leads 3 Value Stocks Offering Estimated Intrinsic Value
As U.S. markets grapple with the implications of newly imposed tariffs and economic uncertainties, investors are increasingly seeking opportunities in undervalued stocks that may offer intrinsic value ...
Signs of hiring at Boston-area life sciences companies
Some of Massachusetts’ largest life sciences employers, as well as smaller biotechs, increased their headcount in 2024, ...
Investing Snacks11h
Vertex’s Journavx Poised for Big Outpatient Market Win
Vertex Pharmaceuticals secured a Buy rating from Leerink Partners analyst David Risinger. The firm’s newly approved pain ...